Opus Genetics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Opus Genetics, Inc. (IRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 730.00 thousand shares for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2017-02-24
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2016-12-31 was 120.00K shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2016-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2015-12-31 was 0.00 shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2015-09-30 was 310.00K shares.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2016 was 730.00K shares, a 58.09% decline from fiscal 2015.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2015 was 1.74M shares, a 4766.26% increase from fiscal 2014.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2014 was 35.80K shares, a 90.45% decline from fiscal 2013.
- Opus Genetics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2013 was 375.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2016-12-31 | 120.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | 120.00K shares derived: sum of 2 quarters · filed 2017-02-24 | 730.00K shares 10-K · filed 2017-02-24 | |
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | 610.00K shares 10-Q · filed 2016-11-04 | ||
| 2016-06-30 | 610.00K shares 10-Q · filed 2016-08-05 | |||
| 2015-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | 310.00K shares derived: sum of 2 quarters · filed 2016-03-14 | 310.00K shares derived: sum of 3 quarters · filed 2016-03-14 | 1.74M shares 10-K · filed 2016-03-14 |
| 2015-09-30 | 310.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | 310.00K shares derived: sum of 2 quarters · filed 2015-11-02 | 1.74M shares 10-Q · filed 2015-11-02 | 1.74M shares derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | 1.43M shares 10-Q · filed 2015-08-07 | 1.43M shares derived: sum of 3 quarters · filed 2015-08-07 | |
| 2015-03-31 | 1.43M shares 10-Q · filed 2015-05-08 | 1.43M shares derived: sum of 2 quarters · filed 2015-05-08 | ||
| 2014-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | 35.80K shares 10-K · filed 2015-03-16 | ||
| 2014-09-30 | 35.80K shares 10-Q · filed 2015-11-02 | |||
| 2013-12-31 | 150.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | 375.00K shares 10-K · filed 2015-03-16 | ||
| 2013-09-30 | 225.00K shares 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |